Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention1: Majoon Dabeedulward (Sugarfree): Majoon Dabeedul ward (Sugarfree) in 500mg capsule form to be taken orally twice daily
Control Intervention1: Placebo: A Placebo (powdered form) 500mg ro
Sponsors
Jamia Hamdard
Eligibility
Inclusion criteria
Inclusion criteria: Age 18-60 years Patient of all genders Patient willing to participate and sign the written informed consent Patient diagnosed as having fatty liver based on the ultrasonography report Patients with/ without clinical signs and symptoms
Exclusion criteria
Exclusion criteria: Age below 18 and above 60 years Use of alcohol or any other drug abuse Patients diagnosed with any coexisting liver disease Pregnant and lactating women Patients suffering with Hypertension, CKD, CAD, CLD or uncontrolled DM,thyroid disorder. Patient having immune-compromised status. Patient using lipid lowering drugs or dietary supplements within the last 3 weeks. Oral contraceptives & corticosteroids. Neurological disorders like epilepsy or psychiatric disorders Patient having history of Pancreatitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abdominal ultrasound - We will assess steatotic liver changes by Quantitative Tissue attenuation measurement with S-Shearwave Imaging Technique before and after drug administrationTimepoint: From baseline to 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Lipid profile Change in lipid profile (Total Cholesterol, HDL,LDL,Triglycerides, VLDL) after therapy (if any) 2)Levels of Alanine transaminase (ALT) - Changes in Alanine transaminase units per litre after therapy (if any) 3)Levels of Aspartate transaminase (AST) - Changes in Aspartate transaminase (AST)units per litre after therapy (if any) 4)Levels of Alkaline phosphatase(ALP) - Changes in Alkaline phosphatase (ALP) in IU after therapy (if any) 5)Levels of Albumin and total protein- Changes in Albumin and total protein in gm/L after therapy (if any) 6) Levels of Bilirubin- Changes in Bilirubin in µmol/L after therapy (if any) 7)Levels of total protein - Changes in total protein in gm/L after therapy (if any) 8)Levels of Gammaglutamyltra nsferase(GGT)- Changes in Gamma-glutamyltransferase (GGT) units per liter after therapy (if any ) 9)Levels of lactate dehydrogenase (LDH)- Changes in L-lactate dehydrogenase (LDH) units per liter after therapyTimepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactAzhar Jabin
Jamia Hamdard
Outcome results
None listed